$KRYS

The Motley Fool on $KRYS (Nov 14, 2026)

AI summary · The Motley Fool

KRYS is a great, profitable, early-growth biotech: marketed Vyjuvek is highly profitable, Q3 revenue was $127 million, up 30% year over year, with 94% gross margin, over $1 billion cumulative revenue and $1.2 billion cash; it is expanding into other rare diseases and internationally and approved a $400 million buyback over two years. A 10%+ post-earnings drop reflected two clinical readouts delayed to 2027, which the speaker says is not worrisome; the stock is at least a watchlist, if not buy-list, name for biotech investors.

BullishHe framed it in years
“4 Stocks to Buy Before the End of 2026!”
The Motley FoolPublished Nov 14 · 12 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

12 passages
5:149:10

Moving on to a completely different sector, we should talk about healthcare. I'm going to talk about Crystal Biotech, and the code is K R Y S.

So, Crystal Biotech, if you're not familiar with it, is a bit of an unknown in the world of emerging biotech companies. This is a company in the commercial phase. They already have a proven and highly profitable product.

So, this is not a bet on the results of a future clinical trial.

Crystal Biotech's flagship product is a treatment called Vyjuvek. It is the world's first gene therapy that can be applied topically at home. It treats a condition known as atrophic epidermal necrolysis or (DEB).

This is a severe and extremely painful hereditary skin disease. It causes horrific ulcers and chronic wounds due to a defect in collagen genes.

Crystal Biotech's Vigovic drug uses a modified version of the herpes virus to deliver a working copy of that gene directly into the patient's skin cells. Therefore, it is actually applied as a simple gel that the patient can use repeatedly at home.

This is not done with a single, one-time injection, you know.

This re-dose delivery platform is not only useful for this one rare disease. It is the foundation that Crystal Biotech is now expanding to include new programs targeting other rare conditions in the lungs, eyes, and other rare skin disorders.

So it's really interesting, you know, how they built their platform around the herpes simplex virus. This is a virus that has evolved over a long period to be good at two things: infecting skin cells and hiding from the body's immune system long enough to remain in a person for life without being permanently eliminated.

Thus, the Crystal Biotic platform actually benefits from these two natural properties, but for a therapeutic purpose. This means they are able to replace a corrective copy of any gene the patient is missing, while preserving the virus’s natural ability to infiltrate skin cells without triggering any kind of negative immune response in the patient.

Now, let's put some numbers on the company's performance; they recently released their third-quarter results in early November. Global revenues reached $127 million. That was a 30% year-on-year increase.

Their cumulative revenue since the launch of Vigovic now stands at just over $1 billion. Their gross profit margin is 94%. They ended the quarter with approximately $1.2 billion in cash and investments.

Now, the stock has come under some pressure since they announced their earnings. It actually dropped by 10% or more on the day of their earnings report. This was primarily because the administration revealed that they had a small number of key clinical data readouts for two of their product line candidates that had been postponed to 2027 instead of being released before the end of the year.

Therefore, they have a therapeutic candidate that targets a rare condition in the eye. They will report preliminary results from their ongoing clinical trials early next year. They have a treatment for cystic fibrosis whose results have now been postponed until the first half of 2027.

This does not indicate anything to worry about in terms of work, but it is just something you should be aware of.

As you know, Crystal Biotechnology continues its international expansion. They have, of course, expanded and launched their products within the United States, and have finalized pricing and payment negotiations in markets such as Germany and Italy.

So they will be launching their products in some of these markets as early as the beginning of 2027. They are already benefiting from early launches in Europe as well as expansion in Japan.

I would also like to point out that the board of directors of Crystal Biotechnology has approved a $400 million share buyback program that will be implemented over the next two years.

So, it's a great company and in its early stages of growth. The company has one major, highly profitable product, but is rapidly expanding into other areas of rare diseases. It is a profitable company with a high profit margin, and it may be one to put on your watchlist at least, if not your buy list, if you are interested in investing your money in biotechnology stocks.

TickerSays